The biotechnology company had announced positive study results for its DCCR tablets on Tuesday.
Soleno Therapeutics stock fell sharply Wednesday, reversing a small portion of its meteoric gains from the previous session.
But smaller biopharmaceutical stocks are notoriously volatile. Soleno stock dropped 15% to $22.90 in recent trading Wednesday, although the shares are still up about 1,056% so far this year, largely thanks to Tuesday’s surge. The company has a market value of $268 million. Prader-Willi Syndrome affects metabolism, and its hallmark symptom is hyperphagia—a chronic feeling of intense, persistent hunger and an intense drive to consume food. Soleno said Tuesday that DCCR showed promise in addressing hyperphagia in a recent clinical development program, and spurring its stock to take off.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trialPliant Therapeutics Inc. shares gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic...
続きを読む »
Amgen discloses more than $400 million stake in recent IPO Neumora TherapeuticsAn Amgen disclosure of a large stake in Neumora Therapeutics indicated the value of its investment in the biotech, which recently went public, has tripled.
続きを読む »
| Kuehne + Nagel International AG Stock Quote (Switzerland: SWX )KNIN | Complete Kuehne + Nagel International AG stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
続きを読む »
San Diego biotech will pay $200K after allegations of misleading claimsBiora Therapeutics made misleading claims regarding the costs of genetic testing services
続きを読む »
Twin Flames Docuseries Dives Deeper Into Couple Behind Matchmaking CultThe three-part Amazon series Desperately Seeking Soulmate: Escaping Twin Flames Universe expands on an explosive investigation first published in Vanity Fair.
続きを読む »